We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
J. Clin. Oncol 2023 Feb 16;[EPub Ahead of Print], M Hussain, B Tombal, F Saad, K Fizazi, CN Sternberg, ED Crawford, N Shore, E Kopyltsov, AR Kalebasty, M Bögemann, D Ye, F Cruz, H Suzuki, S Kapur, S Srinivasan, F Verholen, I Kuss, H Joensuu, MR Smith